|
|
||||||||
Syrrx Inc., San Diego, California 92121, USA
Reprint requests to: Kathleen Aertgeerts, Syrrx Inc., 10410 Science Center Drive, San Diego, CA 92121, USA; e-mail: kathleen.aertgeerts{at}syrrx.com; fax: (858) 550-0526.
The type II transmembrane serine protease dipeptidyl peptidase IV (DPPIV), also known as CD26 or adenosine deaminase binding protein, is a major regulator of various physiological processes, including immune, inflammatory, nervous, and endocrine functions. It has been generally accepted that glycosylation of DPPIV and of other transmembrane dipeptidyl peptidases is a prerequisite for enzyme activity and correct protein folding. Crystallographic studies on DPPIV reveal clear N-linked glycosylation of nine Asn residues in DPPIV. However, the importance of each glycosylation site on physiologically relevant reactions such as dipeptide cleavage, dimer formation, and adenosine deaminase (ADA) binding remains obscure. Individual Asn
Ala point mutants were introduced at the nine glycosylation sites in the extracellular domain of DPPIV (residues 39766). Crystallographic and biochemical data demonstrate that N-linked glycosylation of DPPIV does not contribute significantly to its peptidase activity. The kinetic parameters of dipeptidyl peptidase cleavage of wild-type DPPIV and the N-glycosylation site mutants were determined by using Ala-Pro-AFC and Gly-Pro-pNA as substrates and varied by <50%. DPPIV is active as a homodimer. Size-exclusion chromatographic analysis showed that the glycosylation site mutants do not affect dimerization. ADA binds to the highly glycosylated ß-propeller domain of DPPIV, but the impact of glycosylation on binding had not previously been determined. Our studies indicate that glycosylation of DPPIV is not required for ADA binding. Taken together, these data indicate that in contrast to the generally accepted view, glycosylation of DPPIV is not a prerequisite for catalysis, dimerization, or ADA binding.
Keywords: dipeptidyl peptidase IV; DPPIV; CD26; glycosylation; enzyme activity; ADA; adenosine deaminase binding protein; serine protease
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
C. Y. Edosada, C. Quan, C. Wiesmann, T. Tran, D. Sutherlin, M. Reynolds, J. M. Elliott, H. Raab, W. Fairbrother, and B. B. Wolf Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity J. Biol. Chem., March 17, 2006; 281(11): 7437 - 7444. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Darlington, M. G. Kirchhof, G. Criado, J. Sondhi, and J. Madrenas Hierarchical Regulation of CTLA-4 Dimer-Based Lattice Formation and Its Biological Relevance for T Cell Inactivation J. Immunol., July 15, 2005; 175(2): 996 - 1004. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Weihofen, J. Liu, W. Reutter, W. Saenger, and H. Fan Crystal Structure of CD26/Dipeptidyl-peptidase IV in Complex with Adenosine Deaminase Reveals a Highly Amphiphilic Interface J. Biol. Chem., October 8, 2004; 279(41): 43330 - 43335. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Aertgeerts, S. Ye, M. G. Tennant, M. L. Kraus, J. Rogers, B.-C. Sang, R. J. Skene, D. R. Webb, and G. S. Prasad Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation Protein Sci., February 1, 2004; 13(2): 412 - 421. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |